Istiratumab
Based on 1 Customer Validation
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers.
For research use only. We do not sell to patients.
- Purity: 98.45%
- CAS No.: 1509928-04-4
- Molecular Weight:199.63 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGF1R & ERBB3
In Vitro
Istiratumab (500 nM, 24 h) inhibits AKT activation in response to IGF-1 and HRG costimulation in human pancreatic cancer cell lines[2].
Istiratumab (500 nM, 24 h) inhibits IGF-1- and HRG-induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS mutations[2].
Istiratumab (500 nM, 24 h) induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway[2].
Istiratumab (1 μM, 60 min) block activation of the PI3K and MAPK signaling cascades in ovarian cancer cell lines[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AsPC1, BxPC3, Capan2, CFPAC1, etc.
-
Concentration:500 nM
-
Incubation Time:24 h
-
Result:Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa-[scFv-heavy-lambda]2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1×106 MCF-7 cells labelling ERBB3 (red) with Istiratumab (HY-P99672). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1509928-04-4
-
Appearance Liquid
-
Molecular Weight 199.63 kDa
-
Color Colorless to light yellow
-
SMILES
[Istiratumab]
-
Synonyms
MM 141; MM-005
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. [Content Brief]
[2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. [Content Brief]
[3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)